Royalty Pharma (RPRX) said Friday it has agreed to acquire its external manager, RP Management for about $1.1 billion, including 24.5 million in shares that will vest over five to nine years, about $100 million in cash, and the assumption of $380 million of debt.
The transaction is meant to simplify its corporate structure and reduce costs, generating anticipated cash savings of more than $100 million in 2026 and $175 million in 2030, the company said.
The transaction is expected to close in H1, the company said.
The company said it also approved a new $3 billion share repurchase program, including $2 billion in shares it expects to buy back in 2025.
The repurchase program replaces the unused $465 million of the company's $1.0 billion share repurchase program launched in 2023, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。